Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Posterior Versus Transmuscular Quadratus Lumborum Block in Children Undergoing Lower Abdominal Surgery

3. november 2026 oppdatert av: Kerollos Moneer Neseem Mikhael, Beni-Suef University

Analgesic Efficacy of Posterior Versus Transmuscular Quadratus Lumborum Block in Children Undergoing Unilateral Lower Abdominal Surgery: A Randomized Controlled Trial

The quadratus lumborum block (QLB) is an established regional anesthesia technique that provides somatic and visceral analgesia for abdominal wall procedures in both adult and pediatric populations. Among its standardized approaches, the posterior QLB (QL2-injectate deposited in the lumbar interfascial triangle at the posterior surface of the quadratus lumborum muscle) and the transmuscular QLB (QL3-injectate deposited in the fascial plane between the anterior surface of the quadratus lumborum and psoas major muscles) are widely utilized.

Although cadaveric and radiological studies suggest that transmuscular QLB yields greater anterior and thoracic paravertebral spread compared to the posterior approach, comparative clinical evidence in pediatric populations remains limited.

The objective of this randomized, prospective, double-blind controlled trial is to compare the analgesic efficacy of ultrasound-guided posterior QLB (QL2) versus transmuscular QLB (QL3) using an identical weight-based dose and concentration of local anesthetic (0.4 mL/kg of bupivacaine 0.25%) in children aged 1 to 7 years undergoing elective unilateral lower abdominal surgery (e.g., inguinal herniotomy, orchiopexy, hydrocelectomy). The primary hypothesis is that one approach will provide superior 24-hour cumulative opioid-sparing analgesia compared to the other.

Studieoversikt

Detaljert beskrivelse

Background and Anatomical Rationale:

Truncal fascial plane blocks like the quadratus lumborum block (QLB) play a key role in pediatric multimodal analgesia. While posterior QLB (QL2) targets the lumbar interfascial triangle (LIFT) with minimal anatomical risk to deep structures, transmuscular QLB (QL3) penetrates the QL muscle to deposit local anesthetic in the anterior fascial plane adjacent to the psoas major muscle. This study evaluates whether these anatomical differences translate into distinct clinical analgesic outcomes in pediatric patients.

Anesthetic Protocol and Block Execution:

Following standardized general anesthesia induction and airway securing, children assigned to either group receive an ultrasound-guided unilateral block in the lateral decubitus position using the classic "Shamrock" sonographic landmark view (L3 transverse process level).

Posterior QLB Group (QL2): A short-bevel echogenic needle is advanced in-plane to the posterior aspect of the quadratus lumborum muscle (QLM) within the lumbar interfascial triangle.

Transmuscular QLB Group (QL3): An identical needle is advanced transmuscularly through the QLM into the fascial plane between the anterior surface of the QL and psoas major muscle.

In both groups, plane identification is confirmed by hydrodissection (1-2 mL saline/D5W), followed by slow injection of 0.4 mL/kg bupivacaine 0.25% (1 mg/kg; maximum 20 mL) with intermittent aspiration every 3-5 mL.

Postoperative Analgesic Management and Assessment:

Postoperative behavioral pain intensity is monitored by a blinded observer using the Face, Legs, Activity, Cry, Consolability (FLACC) score at 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively. Stepwise rescue analgesia is initiated for FLACC scores ≥4: intravenous paracetamol 15 mg/kg (if >6 hours from prior dose), followed by rescue intravenous fentanyl 0.5 µg/kg or morphine 0.05 mg/kg if pain persists.

Sedation (University of Michigan Sedation Scale), motor block (modified Bromage scale), time to first rescue request, incidence of postoperative nausea and vomiting (PONV), parental satisfaction (5-point Likert scale), and time to post-anesthesia discharge readiness are systematically evaluated.

Studietype

Intervensjonell

Registrering (Antatt)

70

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Banī Suwayf, Egypt
        • Beni-Suef University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 år til 7 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Children aged 1 to 7 years. American Society of Anesthesiologists (ASA) physical status I or II. Scheduled for elective unilateral lower abdominal surgery under general anesthesia with a planned quadratus lumborum block for postoperative analgesia (e.g., inguinal herniotomy, orchiopexy, hydrocelectomy).

Written informed consent obtained from a parent or legal guardian.

Exclusion Criteria:

Parental or guardian refusal to participate. Known allergy or hypersensitivity to amide local anesthetics. Coagulopathy or active use of anticoagulant or antiplatelet medication. Local skin infection at the intended regional block injection site. Planned bilateral surgical procedure. Significant hepatic, renal, cardiac, or neuromuscular disease. Developmental delay or medical condition precluding reliable pain-scale assessment.

Preoperative chronic opioid or regular analgesic use. Body weight below the 3rd percentile for age, or known spinal/vertebral column anomaly precluding safe block performance.

Emergency surgery.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Posterior QLB (QL2)

Children assigned to this arm receive a single-dose, ultrasound-guided posterior quadratus lumborum block (QL2) performed after induction of general anesthesia and prior to surgical incision. Under ultrasound guidance, a short-bevel echogenic needle is advanced to the posterior surface of the quadratus lumborum muscle within the lumbar interfascial triangle (LIFT). Local anesthetic is deposited following hydrodissection confirmation and negative aspiration.

Ultrasound-guided single-injection posterior quadratus lumborum block performed pre-incisions under general anesthesia. Local anesthetic: 0.4 mL/kg of bupivacaine 0.25% (1 mg/kg; maximum single-side volume 20 mL) deposited at the posterior border of the QL muscle within the lumbar interfascial triangle.

Andre navn:
  • QL2 block
  • Lumbar interfascial triangle block
Aktiv komparator: Transmuscular QLB (QL3)

Children assigned to this arm receive a single-dose, ultrasound-guided transmuscular quadratus lumborum block (QL3) performed after induction of general anesthesia and prior to surgical incision. Under ultrasound guidance using the "Shamrock" view, a short-bevel needle is advanced transmuscularly through the quadratus lumborum muscle to deposit local anesthetic in the fascial plane between its anterior surface and the psoas major muscle following hydrodissection confirmation and negative aspiration.

Ultrasound-guided single-injection transmuscular quadratus lumborum block performed pre-incisions under general anesthesia. Local anesthetic: 0.4 mL/kg of bupivacaine 0.25% (1 mg/kg; maximum single-side volume 20 mL) deposited in the plane between the anterior surface of the QL muscle and psoas major muscle.

Andre navn:
  • Anterior/Lateral QLB
  • Shamrock approach QLB

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total Cumulative Opioid Consumption in the First 24 Hours
Tidsramme: First 24 hours postoperatively

Total cumulative dose of intraoperative and postoperative rescue opioids administered during the first 24 hours postoperatively, converted to intravenous morphine-equivalent doses (mg/kg) using standard conversion ratios and normalized to body weight. A lower numerical value indicates a superior clinical outcome (greater opioid-sparing effect and reduced opioid requirement).

First 24 hours postoperatively

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative Pain Intensity Scores
Tidsramme: At 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively

Postoperative pain intensity measured using the Face, Legs, Activity, Cry, Consolability (FLACC) behavioral pain scale. Scores range from 0 to 10, where 0 represents no pain (relaxed and comfortable; best outcome) and 10 represents severe pain/discomfort (worst outcome). Lower numerical scores represent better pain control.

At 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
Time to First Rescue Analgesia Request
Tidsramme: Up to 24 hours postoperatively

Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU) until the first administration of rescue analgesic (triggered by a FLACC score ≥4). A higher numerical value (longer duration of time) indicates a superior clinical outcome (prolonged block duration and delayed pain onset).

Up to 24 hours postoperatively
Block Execution Time
Tidsramme: Intraoperatively (during block performance)

Total time required to perform the ultrasound-guided regional block, measured in seconds from initial placement of the ultrasound transducer on the skin to needle withdrawal. Lower execution times represent greater technical ease and efficiency (better procedural performance).

Intraoperatively (during block performance)
Number of Needle Passes and Redirections
Tidsramme: Intraoperatively (during block performance)

Number of discrete needle skin punctures and forward redirections required to achieve correct needle tip positioning within the intended target fascial plane. A lower count indicates easier needle placement and less tissue trauma (better procedural outcome).

Intraoperatively (during block performance)
Incidence and Severity of Postoperative Nausea and Vomiting
Tidsramme: At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively

Presence and severity of postoperative nausea and vomiting assessed using a 4-point scale (0 = no nausea or vomiting [best outcome], 1 = mild nausea, 2 = moderate nausea or single emetic episode, 3 = severe nausea or multiple emetic episodes requiring antiemetic rescue [worst outcome]). Lower scores represent a better clinical outcome.

At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
Postoperative Sedation Score
Tidsramme: At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively

Sedation level evaluated using the University of Michigan Sedation Scale (UMSS), ranging from 0 (awake and alert; normal state) to 4 (unarousable to noxious stimuli; severe sedation/respiratory risk). Lower scores (specifically 0 to 1) represent desirable postoperative alertness and faster recovery.

At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
Incidence and Degree of Lower Limb Motor Blockade
Tidsramme: At 1, 4, and 8 hours postoperatively

Motor weakness evaluated using a modified Bromage scale (0 = full flexion of knees and feet / no motor block [best safety outcome], 1 = partial flexion, 2 = movement of feet only, 3 = complete paralysis of lower limb [worst outcome]). A score of 0 indicates an optimal motor-sparing sensory block without unwanted lumbar plexus involvement.

At 1, 4, and 8 hours postoperatively
Parental Satisfaction Score
Tidsramme: 24 hours postoperatively

Parental or legal guardian overall satisfaction with post-surgical pain management evaluated on a 5-point Likert scale (1 = very dissatisfied [worst outcome], 2 = dissatisfied, 3 = neutral, 4 = satisfied, 5 = very satisfied [best outcome]). Higher numerical scores represent a superior clinical outcome.

24 hours postoperatively
Time to Post-Anesthesia Discharge Readiness
Tidsramme: Up to 24 hours postoperatively

Time elapsed (in minutes) from PACU arrival until the child satisfies all criteria of the modified pediatric Post-Anesthesia Discharge Scoring System (PADSS). A lower numerical value (shorter duration of time in minutes) indicates a better outcome (faster recovery and earlier discharge readiness).

Up to 24 hours postoperatively
Incidence of Block-Related Adverse Events and Complications
Tidsramme: Through 24 hours postoperatively

Total count and percentage of procedural complications (including vascular puncture, LAST, peritoneal injury, localized hematoma, or infection). A lower number (ideally 0) indicates a superior safety profile.

Through 24 hours postoperatively

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. april 2027

Studiet fullført (Antatt)

1. mai 2027

Datoer for studieregistrering

Først innsendt

3. november 2026

Først innsendt som oppfylte QC-kriteriene

3. november 2026

Først lagt ut (Faktiske)

9. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data (including primary outcome measures, demographic variables, FLACC pain scores, cumulative opioid consumption, and block execution metrics) will be made available to qualified academic researchers upon reasonable request submitted to the principal investigator, following publication of the primary trial results.

IPD-delingstidsramme

Data will become available 3 months following peer-reviewed journal publication of the primary manuscript and will remain accessible for 3 years.

Tilgangskriterier for IPD-deling

Data will be shared with recognized medical and academic researchers who submit a sound scientific proposal and a signed data-use agreement to the principal investigator (at Kmnmk87@med.bsu.edu.eg).

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere